GYRE
GYRE THERAPEUTICS, INC. · Healthcare
Insiders sold $953K net in the last 90 days ·2 sellers, 0 buyers· 2 of 16 sales under Rule 10b5-1 plans· latest Form 4 filed Jun 22, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$953K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Latest filing
Jun 22, 2026
Ye Weiguo
GYRE THERAPEUTICS, INC. (GYRE) has 9 SEC Form 4 filings (34 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jun 22, 2026.
Inside the rolling window, 2 insiders at GYRE THERAPEUTICS, INC. reported no open-market purchases and 16 open-market sales totaling $953K. The most active filer is Chief Operating Officer Ye Weiguo with 14 filings. Insiders have net sold $953K over the trailing 6 months. The most recent open-market filing is a sale of 17,500 shares by Chief Operating Officer Ye Weiguo, dated Jun 9, 2026, worth $107K.
- Industry:Biotechnology
- CEO:Ying Luo
- Employees:625
- HQ:San Diego, CA, US
- IPO:2006-04-12
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Operating Officer | Sale | 17,500 | $107K | Jun 22 | +23.2% | SEC ↗ | |
| Chief Operating Officer | Sale | 11,418 | $71K | Jun 22 | +23.2% | SEC ↗ | |
| Chief Operating Officer | Sale | 3,000 | $19K | Jun 22 | +23.2% | SEC ↗ | |
| Chief Operating Officer | Sale | 2,800 | $17K | Jun 15 | +28.8% | SEC ↗ | |
| Chief Operating Officer | Sale | 19,575 | $120K | Jun 8 | +24.8% | SEC ↗ | |
| Chief Operating Officer | Sale | 15,401 | $99K | Jun 8 | +24.8% | SEC ↗ | |
| Chief Operating Officer | Sale | 3,500 | $21K | May 27 | +27.5% | SEC ↗ | |
| Chief Operating Officer | Sale | 4,000 | $24K | May 27 | +27.5% | SEC ↗ | |
| Chief Operating Officer | Sale | 9,400 | $58K | May 22 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 12,820 | $79K | May 22 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 200 | $1K | May 20 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 9,120 | $58K | May 20 | — | SEC ↗ | |
Ye WeiguoFirst filing | Chief Operating Officer | Sale | 15,580 | $108K | May 18 | — | SEC ↗ |
Ye WeiguoFirst filing | Chief Operating Officer | Sale | 13,100 | $87K | May 18 | — | SEC ↗ |
Luo YingFirst filing | Chief Executive Officer | Sale | 179 | $1K | May 8 | — | SEC ↗ |
Luo YingFirst filing | Chief Executive Officer | Sale | 10,136 | $81K | May 8 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does GYRE have?
GYRE THERAPEUTICS, INC. (GYRE) has 9 SEC Form 4 filings (34 transaction rows) in the rolling 365-day window, disclosed by 2 distinct insiders. Most recent filing: Jun 22, 2026.
When was the most recent SEC Form 4 filing for GYRE?
The most recent Form 4 filing for GYRE on Tracefour is dated Jun 22, 2026.
Who is the most active insider at GYRE?
The most active SEC Form 4 filer at GYRE in the rolling window is Chief Operating Officer Ye Weiguo, with 14 filings.
What is the net insider flow at GYRE over the last 6 months?
Over the trailing 180 days, insiders at GYRE have net sold $953K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at GYRE in the current window?
Inside the rolling window, insiders at GYRE bought $0 and sold $953K based on SEC Form 4 filings.
Can I get alerts for GYRE insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at GYRE THERAPEUTICS, INC. (GYRE). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
GYRE THERAPEUTICS, INC. is in the Healthcare sector.